Exelixis Inc Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Exelixis Inc (EXEL) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 3.97 million shares for the 12-month period ending 2018-12-28, per its 10-K filed 2019-02-22.
Discontinued › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2019-02-22
- Exelixis Inc antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2018-09-28 was 5.69M shares, a 875.47% increase year-over-year.
- Exelixis Inc antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2018-06-29 was 5.16M shares, a 195.54% increase year-over-year.
- Exelixis Inc antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2018-03-30 was 1.91M shares, a 94.60% decline year-over-year.
- Exelixis Inc antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2017-09-30 was 583.00K shares, a 99.11% decline year-over-year.
- Exelixis Inc antidilutive securities excluded from computation of earnings per share, amount for fiscal 2018 was 3.97M shares, a 141.22% increase from fiscal 2017.
- Exelixis Inc antidilutive securities excluded from computation of earnings per share, amount for fiscal 2017 was 1.65M shares, a 97.37% decline from fiscal 2016.
- Exelixis Inc antidilutive securities excluded from computation of earnings per share, amount for fiscal 2016 was 62.46M shares.
- Exelixis Inc antidilutive securities excluded from computation of earnings per share, amount for fiscal 2016 was 62.46M shares, a 46.83% decline from fiscal 2016.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2018-12-28 | 3.97M shares 10-K · filed 2019-02-22 | |||||||
| 2018-09-28 | 5.69M shares 10-Q · filed 2018-11-01 | 2.94M shares 10-Q · filed 2018-11-01 | ||||||
| 2018-06-29 | 5.16M shares 10-Q · filed 2018-08-01 | 2.61M shares 10-Q · filed 2018-08-01 | ||||||
| 2018-03-30 | 1.91M shares 10-Q · filed 2018-05-02 | |||||||
| 2017-12-29 | 1.65M shares 10-K · filed 2019-02-22 | |||||||
| 2017-09-30 | 583.00K shares 10-Q · filed 2017-11-01 | 1.11M shares 10-Q · filed 2017-11-01 | ||||||
| 2017-09-29 | 583.00K shares 10-Q · filed 2018-11-01 | 1.11M shares 10-Q · filed 2018-11-01 | ||||||
| 2017-06-30 | 1.75M shares 10-Q · filed 2018-08-01 | 1.63M shares 10-Q · filed 2017-08-02 | ||||||
| 2017-03-31 | 35.29M shares 10-Q · filed 2017-05-01 | |||||||
| 2016-12-31 | 62.46M shares 10-K · filed 2017-02-27 | |||||||
| 2016-12-30 | 62.46M shares 10-K · filed 2019-02-22 | |||||||
| 2016-09-30 | 65.78M shares 10-Q · filed 2017-11-01 | 65.78M shares 10-Q · filed 2017-11-01 | ||||||
| 2016-06-30 | 119.64M shares 10-Q · filed 2017-08-02 | 119.64M shares 10-Q · filed 2017-08-02 | ||||||
| 2016-03-31 | 120.37M shares 10-Q · filed 2017-05-01 | |||||||
| 2016-01-01 | 117.48M shares 10-K · filed 2018-02-26 | |||||||
| 2015-12-31 | 117.48M shares 10-K · filed 2017-02-27 | |||||||
| 2015-09-30 | 120.34M shares 10-Q · filed 2016-11-03 | |||||||
| 2015-06-30 | 118.06M shares 10-Q · filed 2016-08-03 | |||||||
| 2015-03-31 | 118.60M shares 10-Q · filed 2016-05-04 | |||||||
| 2014-12-31 | 105.66M shares 10-K · filed 2017-02-27 | |||||||
| 2014-09-30 | 110.98M shares 10-Q · filed 2015-11-10 | |||||||
| 2014-06-30 | 81.43M shares 10-Q · filed 2015-08-11 | |||||||
| 2014-03-31 | 82.61M shares 10-Q · filed 2015-04-30 | |||||||
| 2013-12-31 | 76.97M shares 10-K · filed 2016-02-29 | |||||||
| 2013-09-30 | 81.26M shares 10-Q · filed 2014-11-04 | |||||||
| 2013-06-30 | 73.71M shares 10-Q · filed 2013-08-06 | 73.71M shares 10-Q · filed 2014-07-31 | 73.57M shares 10-Q · filed 2013-08-06 | |||||
| 2013-03-31 | 73.75M shares 10-Q · filed 2014-05-01 | |||||||
| 2012-12-31 | 72.13M shares 10-K · filed 2015-03-02 | |||||||
| 2012-09-30 | 71.40M shares 10-Q · filed 2013-10-30 | 71.90M shares 10-Q · filed 2012-11-07 | ||||||
| 2012-06-30 | 18.92M shares 10-Q · filed 2013-08-06 | 17.67M shares 10-Q · filed 2013-08-06 | 18.92M shares 10-Q · filed 2012-08-02 | |||||
| 2012-03-31 | 19.82M shares 10-Q · filed 2013-05-07 | 19.82M shares 10-Q · filed 2012-05-03 | ||||||
| 2011-12-31 | 9.09M shares 10-K · filed 2014-02-20 | 9.09M shares 10-K · filed 2012-02-22 | ||||||
| 2011-09-30 | 15.50M shares 10-Q · filed 2012-11-07 | 7.40M shares 10-Q · filed 2012-11-07 | ||||||
| 2011-06-30 | 23.71M shares 10-Q · filed 2012-08-02 | |||||||
| 2011-03-31 | 25.17M shares 10-Q · filed 2012-05-03 | |||||||
| 2010-12-31 | 30.78M shares 10-K · filed 2013-02-21 | 30.78M shares 10-K · filed 2012-02-22 | ||||||
| 2009-12-31 | 40.35M shares 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |